Dyadic International Inc. (NASDAQ:DYAI) Stock Short Interest Declines 57.3%

Dyadic International Inc. (NASDAQ:DYAI – Get Free Report) saw a large decrease in short interest in October. As of October 30th, there was short interest totaling 83,236 shares, a decrease of 57.3% from the October 15th total of 194,728 shares. Based on an average daily trading volume, of 83,778 shares, the short-interest ratio is presently 1.0 days. Currently, 0.3% of the company’s stock are sold short.

Hedge Funds Weigh In On Dyadic International

An institutional investor recently bought a new position in Dyadic International stock. Landscape Capital Management L.L.C. acquired a new position in Dyadic International Inc. (NASDAQ:DYAI – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 55,263 shares of the biotechnology company’s stock, valued at approximately $50,000. Landscape Capital Management L.L.C. owned approximately 0.15% of Dyadic International at the end of the most recent quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Dyadic International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 16th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Get Our Latest Stock Analysis on Dyadic International

Dyadic International Price Performance

Dyadic International stock traded down $0.02 during mid-day trading on Friday, reaching $0.33. 189,367 shares of the company traded hands, compared to its average volume of 83,523. Dyadic International has a fifty-two week low of $0.32 and a fifty-two week high of $1.60. The company has a market capitalization of $13.10 million, a price-to-earnings ratio of -1.56 and a beta of 1.10. The firm’s fifty day moving average is $0.42 and its two-hundred day moving average is $0.74.

Dyadic International (NASDAQ:DYAI – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 226.85%. The company had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $1.43 million. As a group, equities research analysts predict that Dyadic International will post -0.15 earnings per share for the current year.

About Dyadic International

(Get Free Report)

Dyadic International is a biotechnology company developing microbial expression systems to produce proteins for human and animal health applications. Its platforms are designed to help partners develop and manufacture biologics, including vaccines, therapeutics and diagnostic products. The company’s technologies include its C1 fungal expression system, based on a non-pathogenic microorganism, and its Dapibus yeast platform. Dyadic licenses these systems and related expertise to collaborators and also pursues development of selected products for health applications.

Recommended Stories

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.